Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Vitamin D Supplementation in Multiple Sclerosis [Phase 3]
Phase 3 clinical trial evaluating vitamin D supplementation in relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2021-11-09Clinical Trial Update: A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 study comparing two oral doses of laquinimod to interferon beta-1a in relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]
Phase 3 clinical trial update assessing efficacy and safety of BCD-063 and Copaxone-Teva in relapsing-remitting multiple sclerosis has compl…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Tecfidera and the Gut Microbiota [Phase 4]
Phase 4 clinical trial update on Tecfidera (dimethyl fumarate) and its relationship with the gut microbiota in relapsing multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Study of Evobrutinib in Participants With RMS [Phase 3]
Phase 3 trial of evobrutinib in relapsing-remitting multiple sclerosis was terminated; results posted in 2021.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) [Phase 3]
A Phase 3 clinical trial evaluating evobrutinib in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) [Phase 1, Phase 2]
Clinical trial update for Sunphenon EGCG in relapsing-remitting multiple sclerosis (SuniMS) completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects [Phase 1]
Phase 1 comparative bioavailability study of BAFIERTAM (monomethyl fumarate) vs Tecfidera (dimethyl fumarate) in healthy subjects; completed…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 [Phase 4]
Phase IIIB-IV long-term follow-up study for CAMMS03409 in relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) [Phase 2]
A Phase 2 clinical trial update on IMU-838 (IMU-838) evaluating efficacy and safety in Relapsing-Remitting Multiple Sclerosis (RRMS) called …
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis [Phase 2]
This Phase 2 trial update reports results for clemastine fumarate as a remyelinating agent in relapsing-remitting multiple sclerosis, with r…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating ACT-128800 for efficacy, safety, and tolerability in relapsing-remitting multiple sclerosis; results were …
-
CLINICAL_TRIALS trial_result · 2021-03-08Clinical Trial Update: Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
A completed clinical trial update from Imperial College London on a patient research cohort for Relapsing-remitting and Secondary Progressiv…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis [Phase 2]
Phase 2 study of M2951 in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) [Phase 3]
A Phase 3 clinical trial evaluating ocrelizumab in relapsing-remitting multiple sclerosis patients with suboptimal response to prior disease…
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) [Phase 3]
Phase 3 extension study assessing BG00012 monotherapy safety and efficacy in relapsing-remitting multiple sclerosis has completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy [Phase 4]
Phase 4 trial update evaluating safety and tolerability in Portuguese participants with relapsing-remitting multiple sclerosis transitioning…
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial updating the biological activity and safety of low-dose interleukin-2 in relapsing multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2020-09-01Clinical Trial Update: Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) [NA]
Clinical trial update on tolerability of Acthar for treating relapses in Relapsing Remitting Multiple Sclerosis; study completed with result…
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 [Phase 3]
Phase 3 tolerability study in relapsing remitting multiple sclerosis (RRMS) completed; results posted.
-
FDA label_change · 2020-05-15FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc., resulting in labeling changes for its multiple scler…
-
CLINICAL_TRIALS trial_result · 2020-03-19Clinical Trial Update: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes [Phase 4]
Phase 4 trial update evaluating Tecfidera (dimethyl fumarate) on multiple sclerosis disease activity and patient-reported outcomes has compl…
-
CLINICAL_TRIALS trial_result · 2020-03-02Clinical Trial Update: A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® [Phase 4]
A Phase 4 trial updating OCT parameter changes in patients with Relapsing Remitting Multiple Sclerosis treated with Gilenya (fingolimod).
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) [Phase 2]
Phase 2 trial update evaluating safety, tolerability and mechanism of action of boswellic acids in relapsing remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Autologous Mesenchymal Stromal Cells for Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 trial assessing autologous mesenchymal stromal cells in relapsing-remitting and secondary progressive multiple sclerosis has compl…